Skip to content
HowShorted

Accelerate Diagnostics, Inc short interest in 2023

In 2023, Accelerate Diagnostics, Inc's disclosed short interest ran from 4.50% of shares outstanding on 13 Jan 2023 to 2.80% on 29 Dec 2023, a change of -1.70 percentage points. The year's high was 5.11% on 15 Mar 2023 and its low 2.24% on 29 Sep 2023, averaging 3.67% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 31.42 days on 15 Sep 2023. Full history: Accelerate Diagnostics, Inc.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Accelerate Diagnostics, Inc in 2023

2023 in figures

Start of year
4.50% (13 Jan 2023)
End of year
2.80% (29 Dec 2023)
Change
-1.70 pp
High
5.11% (15 Mar 2023)
Low
2.24% (29 Sep 2023)
Average
3.67%
Highest days to cover
31.42 (15 Sep 2023)
SEC filings marked
8

Every report in 2023

Accelerate Diagnostics, Inc short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20234.50%15.83
31 Jan 20234.52%26.77
15 Feb 20234.54%20.02
28 Feb 20234.77%11.53
15 Mar 20235.11%12.72
31 Mar 20234.78%12.01results (8-K), 10-K filed
14 Apr 20234.88%28.11
28 Apr 20234.33%11.63
15 May 20234.07%26.58results (8-K), 10-Q filed
31 May 20234.34%23.18
15 Jun 20234.02%12.58
30 Jun 20233.91%18.35
15 Aug 20232.93%17.14results (8-K), 10-Q filed
31 Aug 20232.89%28.02
15 Sep 20232.45%31.42
29 Sep 20232.24%16.19
13 Oct 20232.49%12.46
31 Oct 20232.79%27.56
15 Nov 20232.69%27.2010-Q filed, results (8-K)
30 Nov 20233.01%16.93
15 Dec 20232.70%6.21
29 Dec 20232.80%11.82

See also: Accelerate Diagnostics, Inc's full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.